TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05601115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted therapy
Description: In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy Group
Description: An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
Study: NCT06524934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of virtual reality during the hysteroscopic procedure
Description: In VR group patients underwent hysteroscopy with standard care but the addition of VRT provided by a VR headset and headphones with the use of a Hypno VR software.
Study: NCT05855954

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: controlled low central venous pressure technique (CLCVP)
Description: 20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.
Study: NCT05824065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMA102
Description: 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMA102
Description: 2 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OMA102 - Placebo
Study: NCT04768400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I (MEP)
Description: Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
Study: NCT05895032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12-week exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: usual care
Study: NCT05653791

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal ultrasound
Description: Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
Study: NCT05868057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 1 time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 1 time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 dry suspension
Description: SHR7280 dry suspension 1 time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 dry suspension
Description: SHR7280 dry suspension 1 time
Study: NCT06019325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIB
Description: After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
Study: NCT05954715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic Preconditioning
Description: Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
Study: NCT05697848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy combined with Pain Education
Description: Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients with chronic low back pain receive manual therapy treatment
Study: NCT05885152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
Study: NCT05800535

Intervention type: DRUG
Intervention: Study of the adverse effects of long-term oncological treatments
Description: Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Intervention type: BEHAVIORAL
Intervention: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients
Description: Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
Study: NCT04250727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZYN
Description: 30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZYN
Description: 30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
Study: NCT05656599

Intervention type: DRUG
Intervention: Letermovir
Description: Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
Study: NCT05954715

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
Study: NCT04925206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET-01
Description: Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
Study: NCT05530083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group education
Description: Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional smoking cessation management
Description: Including regular follow-up of smoking status and giving advice of smoking cessation
Study: NCT06528444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grup 1 placebo
Description: placebo 1 capsule (6 mg) /day for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grup 2 dexametasona
Description: dexamethasone 1 capsule (6 mg)/day for 7 days
Study: NCT06234852

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoid withdrawal group
Description: Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid maintenance group
Description: Daily 5-mg prednisolone over 24 weeks
Study: NCT04958083

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multiphase ECG-gated contrast-enhanced CT
Description: Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
Study: NCT06010472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR NK cells (KN5501)
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Study: NCT05969574

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test AMH
Description: Measurement of AMH performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test AMH
Description: Measurement of AMH performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test AMH
Description: Measurement of AMH performed on the day of first consultation

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test AMH
Description: Measurement of AMH performed on the day of first consultation
Study: NCT06199258

Intervention type: DIAGNOSTIC_TEST
Intervention: pulmonary function test
Description: pulmonary function testing

Intervention type: DIAGNOSTIC_TEST
Intervention: pulmonary function test
Description: pulmonary function testing

Intervention type: DIAGNOSTIC_TEST
Intervention: pulmonary function test
Description: pulmonary function testing
Study: NCT06545071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT-O program
Description: NEAT-O's curriculum is designed to interrupt the cycle of negative emotions and opioid use through a multifaceted approach encompassing physiological, psychological, and behavioral strategies. The program includes interactive modules that capture the core therapeutic components of CBT and teach skills to support OUD recovery.
Study: NCT04740827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atogepant 60 mg
Description: Atogepant tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Atogepant matching placebo tablets.
Study: NCT05038774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face Educational Training
Description: 1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Education Material
Description: 1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension.
Study: NCT06184646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prune
Description: 30 g of prune/day
Study: NCT06111651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Intervention
Description: parent training program with an added emphasis on ethnic-racial socialization and healthy lifestyle behaviors
Study: NCT04963127

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode
Description: CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode
Description: CT acquisition using a standard single energy / non-spectral acquisition mode
Study: NCT03974620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: This is an evidence based intervention that aims to improve cognitive functioning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: This is an evidence based intervention that aims to improve cognitive functioning.
Study: NCT05678764

Intervention type: DEVICE
Intervention: Conversational Information Collection Tool
Description: Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
Study: NCT04941599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Hydroxybenzylamine
Description: 2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250 mg three tabs TID (po) for 6 weeks.
Study: NCT04993638

Intervention type: DEVICE
Intervention: hip arthroplasty
Description: Hip prosthesis surgery

Intervention type: DEVICE
Intervention: hip arthroplasty
Description: Hip prosthesis surgery
Study: NCT05749978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asana adjustment
Description: Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
Study: NCT06575764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Heart Priority Programme
Description: The programme is delivered by the Cardiac Rehabilitation (CR) team. It consist of two main parts: 1) an evidence-based identification form to identify patients at risk of dropout due to being in a vulnerable situation and 2) an add-on intervention to standard CR targeted these patients. The add-on intervention encompasses three core elements: 1) Assigning a contact person with specific responsibilities, 2) Systematically communicating patient information to colleagues in the CR team and 3) Systematic follow-up
Study: NCT05906602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Ischemic Conditioning
Description: 10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5 minutes), repeated 5 times for a total of 50 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ischemic Conditioning
Description: Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely in cuff pressure during blood flow restriction to replicate to replicate perceived tightness without arterial blood flow restriction.
Study: NCT06078605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotinamide(Mitovita)
Description: Nicotinamide(VitaminB3)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04889430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Iptacopan 200mg twice daily oral
Study: NCT06487195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-facilitated, Recovery-based Self-illness-management programme
Description: The Peer-RESIM program will consist of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program workbook/manual and psychoeducation programmes developed by the research team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education group
Description: The psychoeducation group (6 subgroups; 10-12 participants per subgroup) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programmes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual only
Description: Participants in the TAU group will receive routine community mental healthcare services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual only
Description: Participants in the TAU group will receive routine community mental healthcare services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual only
Description: Participants in the TAU group will receive routine community mental healthcare services.
Study: NCT05137132

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CARDIO®
Description: CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil
Study: NCT05646875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
Study: NCT05530174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic dosage practice
Description: Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic dosage practice
Description: Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.
Study: NCT05365321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1122
Description: Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WP1122
Description: Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
Study: NCT05483920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-time educational video
Description: One-time educational video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-time educational video plus automated text messaging
Description: Educational video plus automated text messaging
Study: NCT06541470

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cutting needle biopsy
Description: Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abrams needle biopsy
Description: Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
Study: NCT03929211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.